The test panels run on cobas 6800/8800 Systems and can detect and differentiate common respiratory pathogens at the same time. Credit: F Hoffmann-La Roche.

Roche has launched three molecular polymerase chain reaction (PCR) diagnostic test panels to detect and differentiate common respiratory pathogens at the same time.

The common respiratory illnesses include influenza A, influenza B and respiratory syncytial virus (RSV); adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV); and parainfluenza 1, 2, 3 and 4.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new respiratory test panels, designed to test influenza and other common respiratory illnesses, can be run together or alone using one nasopharyngeal swab specimen.

They use a real-time PCR nucleic acid amplification method to detect specific DNA sequences obtained after extraction.

This helps to achieve quick detection and specific measurement of genes from microorganisms that are associated with infectious diseases, cancer and genetic abnormalities.

Roche stated that the flexible syndromic-style test panel provides clinicians with actionable insights sooner when compared to conventional methods and also reduces unnecessary testing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition to improving patient care, the test helps with proper hospital bed management and infection control.

Roche Diagnostics CEO Thomas Schinecker said: “Our latest set of syndromic respiratory solutions allows clinicians to choose the appropriate tests based on the healthcare setting, season and patient needs.

“By testing only what is medically relevant and necessary, we enable targeted therapy, avoid misuse of antibiotics and reduce unnecessary intervention.”

The molecular PCR diagnostic test panels run on the cobas omni–Utility Channel, cobas 6800/8800 Systems.

Furthermore, the company stated that it aims to expand the availability of these tests beyond CE markets in the future.

Earlier this month, Roche entered a definitive agreement with TIB Molbiol Group to acquire all of the company’s outstanding shares to bolster its molecular diagnostics portfolio.